Commercialized kits to assess T-cell responses against SARS-CoV-2 S peptides. A pilot study in health care workers
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
-
SciScore for 10.1101/2021.03.31.21254472: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: This project was approved by the Valle de Hebron Hospital Institutional Clinical Ethical Board of HUVH (PR(AG)113/2021) Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Methods: Antibody responses were measured in the clinical microbiology laboratory using two widely applied commercial CLIA assays; antibodies (IgG, IgM and IgA) to nucleocapsid (N) SARS-CoV-2 protein were detected by the qualitative Elecsys® Anti-SARS-CoV-2 test in a Cobas 8800 system autoanalyzer (both from Roche); IgG antibodies to the Spike protein were measured by the … SciScore for 10.1101/2021.03.31.21254472: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: This project was approved by the Valle de Hebron Hospital Institutional Clinical Ethical Board of HUVH (PR(AG)113/2021) Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Methods: Antibody responses were measured in the clinical microbiology laboratory using two widely applied commercial CLIA assays; antibodies (IgG, IgM and IgA) to nucleocapsid (N) SARS-CoV-2 protein were detected by the qualitative Elecsys® Anti-SARS-CoV-2 test in a Cobas 8800 system autoanalyzer (both from Roche); IgG antibodies to the Spike protein were measured by the quantitative LIAISON® SARS-CoV-2 S1/S2 IgG test in a XL Analyzer (DiaSorin, Cypress, CA, USA). IgAsuggested: NoneAnti-SARS-CoV-2suggested: NoneSoftware and Algorithms Sentences Resources GraphPad Prism v8.01 software was used for both statistical analysis and graphical representation. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:However, they have limitations in the applicability compared with whole IGRA blood assays used here when it comes to use them in a clinical laboratory (13). Availability of a complementary correlate of protection in addition to serology may be invaluable for to two groups, 1) HCW and other professionals with vulnerability factors that need to be reassured of being immunized to SARS-CoV2 before reassuming tasks that have a risk of accidental re-exposure and 2) for immunosuppressed patients that fail to make a measurable antibody response. IGRA Spike peptides test may constitute a very valuable tool in this context as can be applied to a large number of samples producing results in 24h and with promising sensitivity and specificity.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a protocol registration statement.
-